The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 39.00
Ask: 41.00
Change: 0.75 (1.91%)
Spread: 2.00 (5.128%)
Open: 38.50
High: 40.00
Low: 38.50
Prev. Close: 39.25
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Placing to Partially Fund Acquisition

12 Feb 2016 12:11

RNS Number : 9436O
Venture Life Group PLC
12 February 2016
 

12 February 2016

 

Venture Life Group plc

("Venture Life", the "Company" or the "Group")

 

Results of Placing to Partially Fund Acquisition

 

Venture Life, the international consumer healthcare group addressing the self-care needs of the ageing population, is pleased to announce the successful completion of the Placing, in order to partially fund the proposed Acquisition of Periproducts Limited, as announced earlier today.

 

A total of 2,428,572 new ordinary shares (the "Placing Shares") have been placed by Panmure Gordon at a price of 70 pence per share (the "Placing Price") to raise £1.7 million (before expenses) for the Company. The Placing Shares being issued represent approximately 7.1% of the issued ordinary share capital of the Company prior to the Placing. The Placing Price represents a discount of 9.7% to the mid-market closing price on 11 February 2016, being the last practicable day before the announcement of the Placing.

 

Completion of the Placing remains subject, inter alia, to the passing of the Resolutions at a general meeting being convened for 1 March 2016, and on the admission of the Placing Shares to trading on AIM ("Admission").

 

The Company will apply for Admission, conditional upon shareholder approval, to trading on AIM. It is expected that the Circular to convene the general meeting will be posted today, and will also be available on the Company's website shortly at www.venture-life.com/.

 

Jerry Randall, Chief Executive Officer, said:

 

"We are delighted that our placing to help fund the proposed acquisition of Periproducts has received the support of institutional investors at a difficult time for capital markets and we are excited about the prospects for Periproducts' premium oral care product range and the Venture Life Group."

 

Panmure Gordon is acting as Financial Adviser, Nominated Adviser and Corporate Broker in respect of the Placing. Unless the context requires otherwise, capitalised terms in this announcement have the same meanings as defined in the Company's announcement released via RNS at 7 a.m. today.

 

Director participation in the Placing

 

Certain of the Company's directors have agreed to subscribe for, in aggregate, 505,394 Placing Shares at the Placing Price. The interests of those directors participating in the Placing in the current issued share capital of the Company and the Company's issued share capital, as expected to be enlarged by the Placing and immediately following Admission, are set out below:

 

 

No. Ordinary Shares currently held

% of current issued share capital

No. Placing Shares issued

No. Ordinary Shares held immediately following the Placing

% of issued share capital, as enlarged by the Placing

Gianluca Braguti

6,942,602*

20.2

142,857

7,085,459

19.2

Jerry Randall and associated holdings

3,781,129

11.0

150,000

3,931,129

10.7

Sharon Collins

1,384,166

4.0

198,251

1,582,417

4.3

James Hunter

36,697

0.1

7,143

43,840

0.1

Dr Lynn Drummond

11,222

0.03

7,143

18,365

0.05

*Note: the Company has previously disclosed that Gianluca Braguti holds 6,947,602 Ordinary Shares following notification to the Company that Mr. Braguti purchased 20,000 Ordinary Shares in two separate transactions in October 2014. However, after an internal review of the Company's register of members, the Company has confirmed that Mr.Braguti only purchased 15,000 Ordinary Shares in October 2014. Accordingly, the number of Ordinary Shares currently held by Mr.Braguti has been corrected (to 6,942,602) in the table above.

 

Each of the above Director's obligation to participate is conditional upon certain matters and events including, amongst other things, the passing of the Resolutions, the Placing Agreement having become unconditional and Admission of the Placing Shares becoming effective on or before 3 March 2016 (but in any event by no later than 8.00 a.m. on 17 March 2016).

 

Director participation in the Convertible Bond Issue

Certain of the Company's directors, being Mr Gianluca Braguti and Mr Jerry Randall (the "Bondholder Directors"), have today entered into a joint underwriting commitment for £0.4 million of the Convertible Bond Issue. Depending on the success of the auction process for the Convertible Bond Issue, the final amount of Convertible Bonds purchased by the Bondholder Directors may be equal to or less than £0.4 million. Pursuant to the terms of the Convertible Bond Instrument, as described in the announcement made earlier today, the Convertible Bonds purchased by the Bondholder Directors will be convertible into Ordinary Shares at a share price of 87.5 pence, being a 25% premium to the Placing Price. However, the Bondholder Directors may exercise their discretion as to when (if at all) to convert their Convertible Bonds into Ordinary Shares. The Convertible Bond Issue, and the participation of the Bondholder Directors in the issue, is inter-conditional on the completion of the Placing (and vice versa), and also completion of the Acquisition.

 

Related Party Transaction

Where a company enters into a related party transaction, under the AIM Rules the independent directors of the company are required, after consulting with the company's nominated adviser, to state whether, in their opinion, the transaction is fair and reasonable in so far as its shareholders are concerned.

 

Gianluca Braguti is a director of the Company and, as detailed above, has an interest in approximately 6,942,602 Ordinary Shares (representing an interest of approximately 20.2% of the Existing Ordinary Shares) as at the date of this announcement. By virtue of Mr Braguti being a Director in addition to his current interests in the Company, he is considered to be a "related party" as defined under the AIM Rules. AIM Rule 16 requires all transactions between the Company and Mr Braguti completed during the twelve months prior to the latest transaction to be aggregated. Accordingly, Mr Braguti's participation in the Placing and the Convertible Bond Issue constitute a related party transaction for the purposes of Rules 13 and 16 of the AIM Rules.

 

The independent Directors consider, having consulted with the Company's nominated adviser, Panmure Gordon, that the terms of Mr Braguti's participation in the Placing and entry into an underwriting commitment to participate in the Convertible Bond Issue are fair and reasonable insofar as the Company's Shareholders are concerned.

 

 

For further information, please contact:

 

Venture Life Group plc +44 (0)1344 742 870

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer

 

Panmure Gordon +44 (0) 207 886 2500

Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Square One Consulting +44 (0) 207 929 5599

David Bick / Brian Alexander

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBDGDDGBBBGLD
Date   Source Headline
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results
25th Mar 20207:00 amRNSNotice of Results Update and Trading Update
9th Mar 20207:00 amRNSTrading Update and Notice of Results
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Jan 202012:37 pmRNSCompletion of Acquisition
9th Jan 20204:28 pmRNSDirector/PDMR Shareholding
6th Jan 20203:38 pmRNSGrant of Options
19th Dec 20197:00 amRNSAcquisition and Trading Update
18th Nov 20192:02 pmRNSHolding(s) in Company
11th Nov 201911:33 amRNSUltraDEX wins at the Dental Industry Awards 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.